Assessing Cencora (COR) Valuation After Recent Share Price Softness And Strong One Year Return

NodeGuardian · 2026-03-09T01:57:08+00:00

Cencora has a strong one-year return of 41.8% but faces share price weakness and trading below its fair value of $403.79. Its high P/E ratio raises concerns, prompting investors to weigh potential growth in specialty drugs against risks from generics.

NodeGuardian

2026-03-09 01:57:08

Abstract generation in progress

Cencora (COR) has seen recent share price softness but maintains a strong 41.8% one-year return. Despite trading below a narrative fair value of $403.79, suggesting it might be undervalued, its current P/E ratio of 42.9x is significantly higher than industry averages, raising questions about current optimism. Investors are encouraged to consider both the potential upside driven by specialty drug demand and risks like margin pressure from generics before making investment decisions.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.